Skip to main content

Table 2 Follow-up parameters in part II of the study (double-blind)

From: Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  Day 1 Day 3 Day 7 Day 18 Day 30
  rhEPO Placebo rhEPO Placebo rhEPO Placebo rhEPO Placebo rhEPO Placebo
Hematocrit (%) 43.10 ± 0.90 42.70 ± 1.39 41.70 ± 1.00 40.20 ± 1.27 41.40 ± 1.46 38.00 ± 1.91 41.80 ± 1.23 38.60 ± 1.61 42.00 ± 1.06 40.50 ± 1.25
Red blood cell count (106/µl) 4.80 ± 0.12 4.70 ± 0.16 4.60 ± 0.11 4.40 ± 0.13 4.50 ± 0.16 4.20 ± 0.22 4.60 ± 0.15 4.20 ± 0.19 4.70 ± 0.14 4.40 ± 0.16
Thrombocyte count (×103/µl) 226.20 ± 14.12 213.50 ± 11.69 218.00 ± 15.56 218.90 ± 14.14 243.20 ± 19.78 239.40 ± 13.17 344.50 ± 26.61 362.30 ± 39.46 246.40 ± 19.62 282.10 ± 20.76
Serum EPO* (U/l) 10.60 ± 1.58 12.00 ± 1.09 5148.40 ± 1094.64 19.50 ± 2.75 24.40 ± 4.37 31.60 ± 12.59 8.00 ± 1.00 28.50 ± 11.73 14.90 ± 3.56 21.00 ± 5.64
  1. *Determined in the first nine patients of each group only.